PetVivo (PETV) 10-K 28 Jun 24 2024 FY Annual report Financial data

Cover

Cover - USD ($)	12 Months Ended
	Mar. 31, 2024	Jun. 28, 2024	Sep. 30, 2023
Document Type	10-K
Amendment Flag	false
Document Annual Report	true
Document Transition Report	false
Document Period End Date	Mar. 31, 2024
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2024
Current Fiscal Year End Date	--03-31
Entity File Number	001-40715
Entity Registrant Name	PetVivo Holdings, Inc.
Entity Central Index Key	0001512922
Entity Tax Identification Number	99-0363559
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	5151 Edina Industrial Blvd
Entity Address, Address Line Two	Suite 575
Entity Address, City or Town	Edina
Entity Address, State or Province	MN
Entity Address, Postal Zip Code	55439
City Area Code	(952)
Local Phone Number	405-6216
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false
Entity Shell Company	false
Entity Public Float			$ 20,563,529
Entity Common Stock, Shares Outstanding		19,904,852
Documents Incorporated by Reference [Text Block]	There are no annual reports to security holders, proxy information statements, or any prospectus filed pursuant to Rule 424 of the Securities Act of 1933 incorporated herein by reference.
ICFR Auditor Attestation Flag	false
Document Financial Statement Error Correction [Flag]	false
Auditor Name	Assurance Dimensions Inc.
Auditor Firm ID	5036
Auditor Location	Margate, Florida
Common Stock [Member]
Title of 12(b) Security	Common Stock
Trading Symbol	PETV
Security Exchange Name	NASDAQ
Warrants [Member]
Title of 12(b) Security	Warrants
Trading Symbol	PETVW
Security Exchange Name	NASDAQ

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Mar. 31, 2024	Mar. 31, 2023
Current Assets
Cash and cash equivalents	$ 87,403	$ 475,314
Accounts receivable, net of allowance for credit losses	18,669	86,689
Inventory, net	390,076	370,283
Prepaid expenses and other current assets	545,512	491,694
Total Current Assets	1,041,660	1,423,980
Property and Equipment, net	821,656	630,852
Other Assets:
Operating lease right-of-use assets	1,194,348	317,981
Patents and trademarks, net	30,099	38,649
Security deposit	27,490	27,490
Total Other Assets	1,251,937	384,120
Total Assets	3,115,253	2,438,952
Current Liabilities
Accounts payable	821,230	588,713
Accrued expenses	243,030	779,882
Operating lease liability – current portion	190,589	78,149
Notes payable and accrued interest-current portion	157,521	6,936
Total Current Liabilities	1,412,370	1,453,680
Other Liabilities
Operating lease liability (net of current portion)	1,003,759	20,415
Note payable and accrued interest (net of current portion)	13,171	239,832
Total Other Liabilities	1,016,930	260,247
Total Liabilities	2,429,300	1,713,927
Commitments and Contingencies (see Note 10)	0	0
Stockholders’ Equity:
Preferred stock, par value $0.001 per share, 20,000,000 shares authorized, 0 and 0 shares issued and outstanding at March 31, 2024 and March 31, 2023
Common stock, par value $0.001 per share, 250,000,000 shares authorized, 17,058,620 and 10,950,220 shares issued and outstanding at March 31, 2024 and March 31, 2023, respectively	17,059	10,950
Common Stock to be Issued		137,500
Additional Paid-In Capital	83,468,218	72,420,604
Accumulated Deficit	(82,799,324)	(71,844,029)
Total Stockholders’ Equity	685,953	725,025
Total Liabilities and Stockholders’ Equity	$ 3,115,253	$ 2,438,952

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2024	Mar. 31, 2023
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	20,000,000	20,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	17,058,620	10,950,220
Common stock, shares outstanding	17,058,620	10,950,220

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Revenues	$ 968,706	$ 917,162
Cost of Sales	229,180	221,036
Gross Profit	739,526	696,126
Operating Expenses:
Sales and Marketing	3,399,666	3,410,277
Research and Development	1,268,014	996,358
General and Administrative	6,693,186	5,022,943
Total Operating Expenses	11,360,866	9,429,578
Operating Loss	(10,621,340)	(8,733,452)
Other (Expense) Income
Loss on Extinguishment of Debt	(534,366)
Settlement Expense	(180,000)
Extinguishment of payables	386,874
Interest (Expense) Income	(6,463)	15,844
Total Other (Expense) Income	(333,955)	15,844
Loss before taxes	(10,955,295)	(8,717,608)
Net Loss	$ (10,955,295)	$ (8,717,608)
Net Loss Per Share:
Earnings per share, basic	$ (0.78)	$ (0.85)
Earnings per share, diluted	$ (0.78)	$ (0.85)
Weighted Average Common Shares Outstanding:
Weighted average number of shares outstanding, basic	13,969,754	10,222,994
Weighted average number of shares outstanding, diluted	13,969,754	10,222,994

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Equity - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Common Stock To Be Issued [Member]	Total
Balance at Mar. 31, 2022	$ 9,988	$ 69,103,155	$ (63,126,421)		$ 5,986,722
Balance, shares at Mar. 31, 2022	9,988,361
Common stock sold	$ 610	1,388,635			1,389,245
Common stock sold, shares	610,011
Stock issued for services	$ 126	399,714			399,840
Stock issued for services, shares	126,000
Vesting of restricted stock units	$ 177	(177)
Vesting of restricted stock units, shares	177,184
Stock-based compensation		1,462,768			1,462,768
Net loss			(8,717,608)		(8,717,608)
Cash paid to exercise warrants	$ 49	66,509			66,558
Cash paid to exercise warrants, shares	48,664
Common stock subscribed				137,500	137,500
Balance at Mar. 31, 2023	$ 10,950	72,420,604	(71,844,029)	137,500	725,025
Balance, shares at Mar. 31, 2023	10,950,220
Common stock sold	$ 4,685	6,660,254		(137,500)	$ 6,527,439
Common stock sold, shares	4,684,048				6,108,400
Stock issued for services	$ 891	1,489,950			$ 1,490,841
Stock issued for services, shares	890,500
Return of stock issued for services	$ (250)	(537,250)			(537,500)
Return of stock issued for services, shares	(250,000)
Conversion of debt and interest to common stock	$ 549	700,206			700,755
Conversion of debt and interest to common stock, shares	549,340
Value of stock and warrants on extinguishment of debt		509,310			509,310
Cashless warrant exercise	$ 34	(34)
Cashless warrant exercise, shares	34,678
Vesting of restricted stock units in lieu of compensation	$ 51	115,544			115,595
Vesting of restricted stock units in lieu of compensation, shares	50,500
Vesting of restricted stock units	$ 149	(149)
Vesting of restricted stock units, shares	149,334
Stock-based compensation		2,109,783			2,109,783
Net loss			(10,955,295)		(10,955,295)
Balance at Mar. 31, 2024	$ 17,059	$ 83,468,218	$ (82,799,324)		$ 685,953
Balance, shares at Mar. 31, 2024	17,058,620

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
CASH FLOWS FROM OPERATING ACTIVITIES
Net Loss for the year	$ (10,955,295)	$ (8,717,608)
Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities:
Stock-based compensation	2,109,783	1,462,768
Depreciation and amortization	126,850	114,434
Investor relations services paid in stock	452,432	507,600
Consulting services paid in stock	405,221
Stock issued in lieu of compensation	115,595
Loss on extinguishment of debt	534,366
Interest on convertible debentures	5,699
Extinguishment of payables	(385,874)
Changes in Operating Assets and Liabilities
Decrease (increase) in prepaid expenses and other assets	41,870	(66,450)
Decrease (increase) in accounts receivable	68,020	(84,093)
Increase in inventory	(19,793)	(271,970)
Increase in accounts payable and accrued expenses	81,538	260,836
Net Cash Used In Operating Activities	(7,419,588)	(6,794,483)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of equipment	(309,104)	(423,934)
Net Cash Used in Investing Activities	(309,104)	(423,934)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from the sale of common stock and warrants	6,527,439	1,389,245
Proceeds from issuance of convertible debentures	670,000
Proceeds from issuance of note payable	150,000
Proceeds from common stock to be issued		137,500
Proceeds from exercise of warrants		66,558
Repayments of notes payable	(6,658)	(6,399)
Net Cash Provided by Financing Activities	7,340,781	1,586,904
Net (Decrease) Increase in Cash	(387,911)	(5,631,513)
Cash at Beginning of Year	475,314	6,106,827
Cash at End of Year	87,403	475,314
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Interest	1,573	2,842
SUPPLEMENTAL DISCLOSURE ON NON-CASH FINANCING AND INVESTING ACTIVITIES
Convertible debentures and accrued interest converted to common stock	700,755
Prepaid stock granted for investor relations services	216,978	399,840
Increase to operating lease right of use asset and operating lease liability	$ 876,367	$ 88,013

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($)	12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Pay vs Performance Disclosure [Table]
Net Income (Loss)	$ (10,955,295)	$ (8,717,608)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Mar. 31, 2024
Insider Trading Arrangements [Line Items]
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION	12 Months Ended
	Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION	NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION (A) Organization and Description The Company is in the business of licensing and commercializing our proprietary medical devices and biomaterials for the treatment and/or management of afflictions and diseases in animals, initially for dogs and horses. The Company began commercialization of its lead product Spryng™ with OsteoCushion™ Technology, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions such as osteoarthritis in dogs and horses in September 2021. The Company has a pipeline of additional products for the treatment of animals in various stages of development. A portfolio of nineteen patents protects the Company’s biomaterials, products, production processes and methods of use. The Company’s operations are conducted from its headquarter facilities in suburban Minneapolis, Minnesota. (B) Basis of Presentation PetVivo Holdings, Inc. (the “Company”) was incorporated in Nevada under a former name in 2009 and entered its current business in 2014 through a stock exchange reverse merger with PetVivo, Inc., a Minnesota corporation. This merger resulted in PetVivo, Inc. becoming a wholly-owned subsidiary of the Company. In April 2017, the Company acquired another Minnesota corporation, Gel-Del Technologies, Inc., through a statutory merger, which is also a wholly-owned subsidiary of the Company. (C) Principles of Consolidation The accompanying consolidated financial statements include the accounts of the Company and its two wholly-owned Minnesota corporations, Gel-Del Technologies, Inc. and PetVivo, Inc. All intercompany accounts have been eliminated during consolidation. (D) Use of Estimates In preparing financial statements in conformity with generally accepted accounting principles, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include collectability of accounts receivable, inventory obsolescence, estimated useful lives and potential impairment of property and equipment and intangibles, estimate of fair value of share-based payments, distributor rebate payable, provision for product returns, right of use lease assets and liabilities and valuation of deferred tax assets. (E) Cash and Cash Equivalents The Company considers all highly-liquid, temporary cash investments with original maturity of three months or less to be cash equivalents. The Company had no (F) Concentration Risk The Company maintains its cash with various financial institutions, which at times may exceed federally insured limits. At March 31, 2024 and 2023, the Company did not have cash balances in excess of the federally insured limits. (G) Accounts Receivable Accounts receivable consists primarily of amounts due from a distributor (see revenue recognition). Accounts receivable is recorded based on management’s assessment of the expected consideration to be received, based on a detailed review of historical collections. Management relies on the results of the assessment, which includes payment history of the applicable payer as a primary source of information in estimating the collectability of our accounts receivable as well as a forecast of projected credit losses. We update our assessment on a quarterly basis, which to date has not resulted in any material adjustments to the valuation of our accounts receivable since all receivables to date have been collected. We believe the assessment provides reasonable estimates of our accounts receivable valuation, and therefore we believe that substantially all accounts receivable are fully collectible. Accordingly, as of March 31, 2024 and 2023, our allowance for credit losses was zero In fiscal 2023, the Company has adopted an accounting standard: Adoption of ASC 326, Financial Instruments - Credit Losses, which amends the impairment model by requiring entities to use a forward-looking approach to estimate lifetime expected credit losses on certain types of financial instruments, including trade receivables (H) Inventory Inventories are recorded in accordance with Accounting Standards Codification (“ASC”) 330, Inventory, and are stated at the lower of cost or net realizable value. We account for inventories using the first in first out (“FIFO”) methodology. Provisions for inventory obsolescence are charged to Cost of Sales. There were no (I) Property & Equipment Property and equipment are recorded at cost. Expenditures for major additions and betterments are capitalized. Maintenance and repairs are charged to operations as incurred. Depreciation is computed by the straight-line method (after considering their respective estimated residual values) over the assets estimated useful life of 3 5 5 7 (J) Patents and Trademarks The Company capitalizes direct costs for the maintenance and advancement of their patents and trademarks and amortizes these costs over the lesser of the useful life of 60 (K) Loss Per Share Basic loss per share is computed by dividing net loss by weighted average number of shares of common stock outstanding during each period. Diluted loss per share is computed by dividing net loss by the weighted average number of shares of common stock, common stock equivalents and potentially dilutive securities outstanding during the period. The Company had 7,768,946 1.20 6.67 3.29 The Company had 32,000 The Company had 1,509,122 1.39 2.79 1.98 The Company had 3,562,817 1.20 5.63 5.05 The Company had 256,804 The Company had 884,849 1.39 2.79 2.19 The Company uses the guidance in Accounting Standards Codification (“ASC”) 260 to determine if-converted loss per share. ASC 260 states that convertible securities should be considered exercised on the latter of the first day of the reporting period’s quarter or the inception date of the debt instrument. Also, the if-converted method shall not be applied for the purposes of computing diluted EPS if the effect would be anti-dilutive. (L) Revenue Recognition The Company recognizes revenue in accordance with ASC 606 “Revenue from Contracts with Customers.” The Company derives revenue from the sale of its pet care products directly to its veterinarian customers in the United States. The Company recognizes revenue when performance obligations under the terms of a contract with the veterinarian customer are satisfied. Product sales occur once control or title is transferred based on the commercial terms. Revenue is recognized upon delivery to the customer, which is when control of these products is transferred and in an amount that reflects the consideration the Company expects to receive for these products. Shipping costs charged to customers are reported as an offset to the respective shipping costs. The Company does not have any significant financing components as payment is received at or shortly after the point of sale. The Company entered into a Distribution Services Agreement (the “Agreement”) with MWI Veterinary Supply Co. (the “Distributor”) on June 17, 2022. Contracts with the Distributor are evidenced by individual executed purchase orders subject to the terms of the Agreement. The contracts consist of a single performance obligation related to the sale of our pet care products. Product sales occur once control or title is transferred based on the commercial terms in the Agreement. Revenue is recognized upon delivery to the Distributor; payment is due within 60 days. The Agreement provides for a distribution fee payable to the Distributor equal to 5 For the year ended March 31, 2024 and 2023, the Company recognized revenue from product sales under the Agreement of $ 626,176 636,345 65 69 Assets and liabilities (included in accrued expenses) under the Agreement were as follows: SCHEDULE OF RECOGNIZED REVENUE ASSETS AND LIABILITIES March 31, 2024 March 31, 2023 Accounts receivable $ 18,669 $ 81,510 Rebate liability 57,264 28,000 Distribution fee payable 7,583 5,187 The Company entered into a Distribution Services Agreement (the “Agreement”) with Covetrus North America LLC (“Covetrus”) on December 18, 2023. Contracts with Covetrus are evidenced by individual executed purchase orders subject to the terms of the Agreement. The contracts consist of a single performance obligation related to the sale of our pet care products. Product sales occur once control or title is transferred based on the commercial terms in the Agreement. Revenue is recognized upon delivery to the Distributor; payment is due within 60 days. The Agreement provides for a rebate payable to the Distributor based on annual sales volume that is retroactively applied. The rebate is estimated under the expected value method and is netted against revenue. Sales are subject to various right of return provisions; the Company uses an expected value method to estimate returns and has determined that any returns would be immaterial as of March 31, 2024. As a result, there is no return liability recorded. Shipping and handling costs are a fulfillment activity and are reported as cost of sales. For the year ended March 31, 2024, the Company recognized revenue from product sales to Covetrus of $ 105,637 11 no (M) Research and Development The Company expenses research and development costs as incurred. (N) Fair Value of Financial Instruments The Company applies the accounting guidance under ASC 820-10, “Fair Value Measurements”, as well as certain related Financial Accounting Standards Board (“FASB”) staff positions. This guidance defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact business and considers assumptions that marketplace participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance. The guidance also establishes a fair value hierarchy for measurements of fair value as follows: ● Level 1 - quoted market prices in active markets for identical assets or liabilities. ● Level 2 - inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. ● Level 3 - unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The Company’s financial instruments consist of accounts receivable, accounts payable, accrued expenses and note payable and accrued interest. The carrying amount of the Company’s financial instruments approximates their fair value as of March 31, 2024, and March 31, 2023, due to the short-term nature of these instruments and the Company’s borrowing rate of interest. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability. The valuation of the Company’s note recorded at fair value is determined using Level 3 inputs, which consider (i) time value, (ii) current market, and (iii) contractual prices. The Company had no (O) Stock-Based Compensation Stock-based compensation is accounted for based on the requirements of ASC 718 – “Compensation – Stock Compensation” which requires recognition in the financial statements of the cost of employee, director, and non-employee services received in exchange for an award of equity instruments over the period the employee, director, or non-employee is required to perform the services in exchange for the award (presumptively, the vesting period). The ASC also requires measurement of the cost of employee, director, and non-employee services received in exchange for an award based on grant-date fair value of the award. The Company has elected to recognize forfeitures as they occur as permitted under Accounting Standards Update (“ASU”) 2016-09 Improvements to Employee Share-Based Payment. (P) Income Taxes The Company accounts for income taxes under ASC 740. Deferred tax assets and liabilities are determined based upon differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. As required by ASC 450, the Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority. The Company is not currently under examination by any federal or state jurisdiction. The Company’s policy is to record tax-related interest and penalties as a component of operating expenses. (Q) Recent Accounting Pronouncements The Company has reviewed the FASB issued ASU accounting pronouncements and interpretations thereof that have effectiveness dates during the periods reported and in future periods. The Company has carefully considered the new pronouncements that alter previous generally accepted accounting principles and does not believe that any new or modified principles will have a material impact on the Company’s reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of the Company’s financial management. In August 2020, the FASB issued ASU 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40) - Accounting for Convertible Instruments and Contracts on an Entity’s Own Equity. The ASU simplifies accounting for convertible instruments by removing major separation models required under current GAAP. Consequently, more convertible debt instruments will be reported as a single liability instrument with no separate accounting for embedded conversion features. The ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception, which will permit more equity contracts to qualify for the exceptions. The ASU also simplifies the diluted net income per share calculation in certain areas. The new guidance is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years, and early adoption is permitted. The Company is currently evaluating the impact of the adoption of the standard on the consolidated financial statements. In June 2016, the FASB issued ASU 2016-13, “Financial Instruments-Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments,” which replaces the existing “incurred loss” model for recognizing credit losses with an “expected loss” model referred to as the CECL model. Under the CECL model, the Company is required to present certain financial assets carried at amortized cost, such as accounts receivable, at the net amount expected to be collected. The measurement of expected credit losses is based on information about past events, including historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. The Company adopted this standard in the consolidated financial statements for the twelve months ended March 31, 2024. The change had no impact on the Company’s financial statements. We believe the critical accounting policies (Item 7 Management’s Discussion and Analysis of Financial Condition and Results of Operation) involve the most significant judgments and estimates used in the preparation of the consolidated financial statements. All other newly issued but not yet effective accounting pronouncements have been deemed either immaterial or not applicable.

RECLASSIFICATION OF PRIOR YEAR

RECLASSIFICATION OF PRIOR YEAR PRESENTATION	12 Months Ended
	Mar. 31, 2024
Accounting Changes and Error Corrections [Abstract]
RECLASSIFICATION OF PRIOR YEAR PRESENTATION	NOTE 2 – RECLASSIFICATION OF PRIOR YEAR PRESENTATION Reclassification. Certain prior year amounts have been reclassified for consistency with the current year presentation in the Consolidated Statements of Operations related to Total Cost of Sales to exclude certain research and development costs and added as an Operating Expense. There were no reclassifications made to the Consolidated Balance Sheets, Consolidated Statements of Changes in Stockholders’ Equity or Consolidated Statements of Cash Flows.

INVENTORY

INVENTORY	12 Months Ended
	Mar. 31, 2024
Inventory Disclosure [Abstract]
INVENTORY	NOTE 3 – INVENTORY As of March 31, 2024 and 2023, the Company had inventory of $ 390,076 370,283 The inventory components are as follows: SCHEDULE OF INVENTORY March 31, 2024 March 31, 2023 Finished goods $ 35,442 $ 13,159 Work in process 20,289 53,398 Raw materials 334,345 303,726 Total Net $ 390,076 $ 370,283

PREPAID EXPENSES AND OTHER ASSE

PREPAID EXPENSES AND OTHER ASSETS	12 Months Ended
	Mar. 31, 2024
Prepaid Expenses And Other Assets
PREPAID EXPENSES AND OTHER ASSETS	NOTE 4 – PREPAID EXPENSES AND OTHER ASSETS The table below shows our prepaid expenses and other assets for the periods ending March 31, 2024 and 2023. SCHEDULE OF PREPAID EXPENSES AND OTHER ASSETS March 31, 2024 March 31, 2023 Investor relations services $ 217,000 $ 115,000 Insurance 138,000 130,000 Nasdaq and FINRA fees 67,000 63,000 Trade shows 44,000 42,000 Consulting 26,000 56,000 Rent 25,000 20,000 Software subscription fees 20,000 19,000 Supplier advance - 42,000 Other 8,512 4,694 Total $ 545,512 $ 491,694

PROPERTY AND EQUIPMENT

PROPERTY AND EQUIPMENT	12 Months Ended
	Mar. 31, 2024
Property, Plant and Equipment [Abstract]
PROPERTY AND EQUIPMENT	NOTE 5– PROPERTY AND EQUIPMENT The components of property and equipment were as follows: SCHEDULE OF PROPERTY AND EQUIPMENT March 31, 2024 March 31, 2023 Leasehold improvements $ 418,041 $ 216,159 Production equipment 661,204 577,067 R&D equipment 25,184 25,184 Computer equipment and furniture 144,817 121,732 Total, at cost 1,249,246 940,142 Accumulated depreciation (427,590 ) (309,290 ) Total Net $ 821,656 $ 630,852 During the year ended March 31, 2024 and 2023, depreciation expense was $ 118,300 104,631

PATENTS AND TRADEMARKS

PATENTS AND TRADEMARKS	12 Months Ended
	Mar. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
PATENTS AND TRADEMARKS	NOTE 6 – PATENTS AND TRADEMARKS The components of patents and trademarks, all of which are finite-lived, were as follows: SCHEDULE OF COMPONENTS OF PATENTS AND TRADEMARKS March 31, 2024 March 31, 2023 Patents $ 3,870,057 $ 3,870,057 Trademarks 26,142 26,142 Total at cost 3,896,199 3,896,199 Accumulated Amortization (3,866,100 ) (3,857,550 ) Total net $ 30,099 $ 38,649 During the year ended March 31, 2024 and 2023, amortization expenses was $ 8,550 9,803

ACCRUED EXPENSES

ACCRUED EXPENSES	12 Months Ended
	Mar. 31, 2024
Payables and Accruals [Abstract]
ACCRUED EXPENSES	NOTE 7 – ACCRUED EXPENSES The components of accrued expenses were as follows: SCHEDULE OF COMPONENTS OF ACCRUED EXPENSES March 31, 2024 March 31, 2023 Accrued payroll and related taxes $ 111,353 $ 258,978 Accrued expenses 131,677 188,666 Accrued lease termination expense - 332,238 Total $ 243,030 $ 779,882 Pursuant to a lease wherein our subsidiary, Gel-Del Technologies, Inc., was the lessee until and through the lease’s termination in fiscal year 2018, the Company had recorded $ 332,238 53,636 385,874

NOTE PAYABLE

NOTE PAYABLE	12 Months Ended
	Mar. 31, 2024
Debt Disclosure [Abstract]
NOTE PAYABLE	NOTE 8 – NOTE PAYABLE In January 2020, the Company entered into a lease amendment for our corporate office facility whereby the lease term was extended through November of 2026 in exchange for a loan of $ 42,500 6 20,528 27,351 7,356 13,171 6,936 20,415 In October 2023 and amended in November 2023, the Company entered into a promissory note for $ 120,000 10 February 2024 0.75 On February 5, 2024, the note and accrued interest of $ 123,255 164,340 In March 2024, the Company entered into a convertible promissory note for $ 150,000 10 0,70 150,000 300,000 300,000 1,558 430,798 430,798 1.50

RETIREMENT PLAN

RETIREMENT PLAN	12 Months Ended
	Mar. 31, 2024
Retirement Benefits [Abstract]
RETIREMENT PLAN	NOTE 9 – RETIREMENT PLAN In February 2021, the Company established a 401(k) retirement plan for its employees in which eligible employees can contribute a percentage of their compensation. The Company may also make discretionary contributions. For the year ended March 31, 2024 and 2023, the Company made contributions to the plan of $ 51,441 35,266

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Mar. 31, 2024
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 10 – COMMITMENTS AND CONTINGENCIES Lease Obligations We lease property and equipment under operating leases, typically with terms greater than 12 months, and determine if an arrangement contains a lease at inception. In general, an arrangement contains a lease if there is an identified asset and we have the right to direct the use of and obtain substantially all of the economic benefit from the use of the identified asset. We record an operating lease liability at the present value of lease payments over the lease term on the commencement date. The related right of use (‘‘ROU”) operating lease asset reflects rental escalation clauses, as well as renewal options and/or termination options. The exercise of lease renewal and/or termination options is at our discretion and is included in the determination of the lease term and lease payment obligations when it is deemed reasonably certain that the option will be exercised. When available, we use the rate implicit in the lease to discount lease payments to present value; however, certain leases do not provide a readily determinable implicit rate. Therefore, we must estimate our incremental borrowing rate to discount the lease payments based on information available at lease commencement. We classify our leases as buildings, vehicles or computer and office equipment and do not separate lease and non-lease components of contracts for any of the aforementioned classifications. In accordance with applicable guidance, we do not record leases with terms that are less than one year on the Consolidated Balance Sheets. None of our lease agreements contain material restrictive covenants or residual value guarantees. Buildings The Company entered into an eighty-four 3,577 2 In January 2020, the Company entered into a lease amendment to extend the lease term through November of 2026 42,500 2,340 2,294 The Company entered into a sixty-three 2,400 2.5 2,808 2,740 On January 10, 2023, the Company entered into a new lease agreement for approximately 14,000 8,420 2.5 The lease will terminate on June 30, 2033 five years 8,420 Vehicles We leased vehicles for certain members of our field sales organization in the year ended March 31, 2024, under a vehicle fleet program whereby the noncancelable lease is for a term of 48 150,000 Operating lease expense for the years ended March 31, 2024, and 2023, was $ 79,381 81,531 The following is a maturity analysis of the approximate annual undiscounted cash flows of the operating lease liabilities as of March 31, 2024: SCHEDULE OF MATURITY OF ANNUAL UNDISCOUNTED OPERATING LEASE LIABILITY 2024 $ 41,000 2025 222,000 2026 226,000 2027 180,000 2028 114,000 2029 114,000 Thereafter 519,000 Total 1,416,000 Less: amount representing interest (222,000 ) Total $ 1,194,000 In compliance with ASC 842, the Company recognized, based on the extended lease terms to June 2026, November 2026, March 2027, and June 2033 0.12 0.40 7.6 4.39 1,194,000 4.7 4.15 SCHEDULE OF BASE RENT LEASE PAYMENTS Present value of future base rent lease payments $ 1,194,348 Base rent payments included in prepaid expenses - Present value of future base rent lease payments – net $ 1,194,348 As of March 31, 2024, the present value of future base rent lease payments – net is classified between current and non-current assets and liabilities as follows: SCHEDULE OF LEASE CURRENT AND NON-CURRENT ASSETS AND LIABILITIES Operating lease right-of-use asset $ 1,194,348 Total operating lease assets 1,194,348 Operating lease current liability 190,589 Operating lease non-current liability 1,003,759 Total operating lease liabilities $ 1,194,348 Employment Agreements The Company has employment agreements with its executive officers. As of March 31, 2024, these agreements contain severance benefits ranging from one month to six months if terminated without cause. Legal Proceedings David Masters, a former employee, board member, and consultant to the Company, has threatened to file suit against the Company to recover in excess of $ 2 180,000 In September 2023, Masters executed the long-term agreement, and the Company recorded a settlement expense of $ 180,000

GOING CONCERN

GOING CONCERN	12 Months Ended
	Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
GOING CONCERN	NOTE 11 - GOING CONCERN The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, which contemplate continuation of the Company as a going concern. The Company incurred net losses of $ 10,955,295 7,419,588 82,799,324 Management believes that the actions presently being taken to further implement its business plan will enable the Company to continue as a going concern. While the Company believes in its ability to raise additional funds, there can be no assurances to that effect. The ability of the Company to continue as a going concern is dependent upon the Company’s ability to further implement its business plan and raise additional funds. These financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

STOCKHOLDERS_ EQUITY

STOCKHOLDERS’ EQUITY	12 Months Ended
	Mar. 31, 2024
Equity [Abstract]
STOCKHOLDERS’ EQUITY	NOTE 12 – STOCKHOLDERS’ EQUITY Equity Incentive Plan On July 10, 2020, our Board of Directors unanimously approved the PetVivo Holdings, Inc “2020 Equity Incentive Plan” (the “2020 Plan”), which authorized the issuance of up to 1,000,000 1,000,000 3,000,000 822,605 Employees, consultants, and advisors of the Company (or any subsidiary), and non-employee directors of the Company will be eligible to receive awards under the Amended Plan. In the case of consultants and advisors, however, their services cannot be in connection with the offer and sale of securities in a capital-raising transaction nor directly or indirectly to promote or maintain a market for PetVivo common stock. The Amended Plan is administered by the Compensation Committee of our Board of Directors (the “Committee”), which has full power and authority to determine when and to whom awards will be granted, and the type, amount, form of payment, any deferral payment, and other terms and conditions of each award. Subject to provisions of the Amended Plan, the Committee may amend or waive the terms and conditions, or accelerate the exercisability, of an outstanding award. The Committee also has the authority to interpret and establish rules and regulations for the administration of the Amended Plan. In addition, the Board of Directors may also exercise the powers of the Committee. The aggregate number of shares of PetVivo common stock available and reserved to be issued under the Amended Plan is 3,000,000 ● the maximum aggregate number of shares of Common Stock granted as an Award to any Non-Employee Director in any one Plan Year will be 10,000 Awards can be granted for no cash consideration or for any cash and other consideration as determined by the Committee. Awards may provide that upon the grant or exercise thereof, the holder will receive cash, shares of PetVivo common stock, other securities or property, or any combination of these in a single payment, installments or on a deferred basis. The exercise price per share of any stock option and the grant price of any stock appreciation right may not be less than the fair market value of PetVivo common stock on the date of the grant. The term of any award cannot be longer than ten years from the date of the grant. Awards will be adjusted in the event of a stock dividend or other distribution, recapitalization, forward or reverse stock split, reorganization, merger or other business combination, or similar corporate transaction, in order to prevent dilution or enlargement of the benefits or potential benefits provided under the Amended Plan. The Amended Plan permits the following types of awards: stock options, stock appreciation rights, restricted stock awards, restricted stock units, deferred stock units, performance awards, non-employee director awards, other stock-based awards, and dividend equivalents. Convertible Debentures On July 27, 2023, the Company issued convertible promissory notes (“Convertible Debentures”) in the aggregate amount of $ 550,000 January 26, 2024 10 2 On August 11, 2023, the Company entered into Convertible Debenture Conversion Agreements (“Conversion Agreements”) with the three debenture holders (“Debenture Holders”). Pursuant to the Conversion Agreements, each Debenture Holder agreed to voluntarily and immediately convert the outstanding balance on their Convertible Debenture into shares of the Company’s common stock prior to January 26, 2024 1.50 1.60 550,000 27,500 385,000 385,000 2.00 As a result of the inducement to the Debenture Holders to voluntarily convert the outstanding balance of their Convertible Debentures prior to their maturity date, the Company recognized a loss on extinguishment of debt of $ 534,366 463,476 45,834 25,056 2,444 509,310 On February 5, 2024, Alan Sarroff, a related party, due to being a greater than 10% shareholder of the Company converted an outstanding promissory note dated October 16, 2023, as amended on November 13, 2023 (the “Convertible Note”), in the amount of $ 120,000 3,255 164,340 May 14, 2024 10 0.75 Sale of Common Stock On August 4, 2023, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with two accredited investors (the “Investors”), pursuant to which the Company agreed to issue and sell to the Investors in a registered direct offering (the “Registered Offering”) 1,200,002 1.50 1,200,002 1,775,782 24,218 502,417 1,273,365 2.00 On December 6, 2023, the Company entered into a Private Offering (the “Purchase Agreement”) with five accredited investors (the “Investors”), pursuant to which the Company agreed to issue and sell to the Investors in a direct offering 352,224 0.90 352,224 317,000 27,000 145,820 171,180 1.50 On February 2, 2024, the Company sold 1,386,469 0.90 1,247,819 1.50 Common Stock For the year ended March 31, 2024, the Company issued 6,108,400 i) 793,585 2,182,359 88,765 2.75 137,500 ii) From April 2023 through June 2023, 30,300 74,589 iii) From April 2023 through June 2023, 49,998 123,078 iv) From July 2023 through September, 2023, 349,498 740,978 v) In August 2023, sale of 1,200,002 1,775,782 24,218 1.50 vi) In August 2023, 385,000 577,500 27,500 1.50 vii) From August 2023 through September 2023, 34,678 63,584 1.34 viii) From July 2023 through August 2023, 28,250 ix) In August 2023, 20,200 41,006 x) 125,000 200,000 xi) ( 250,000 537,500 xii) During November and December 2024, an aggregate of 674,000 959,033 65,779 893,254 xiii) From October 2023 through December 2023, 167,004 293,123 xiv) During October through December 2023, 11,250 xv) During December 2023, 352,224 290,000 xvi) In January 2024, 1,386,469 1,247,819 xvii) During January through March 2024, 109,834 xviii) During January through March 2024, 324,000 423,216 xix) In February 2024, 164,340 123,255 3,255 .75 xx) During February 2024, 152,768 1,247,819 For the year ended March 31, 2023, the Company issued 961,859 i) 24,217 1.33 32,188 ii) 24,447 1.41 34,370 iii) 25,000 49,920 iv) 177,184 10,000 22,000 1,250 11,250 10,000 122,684 v) 610,011 1,389,245 2.32 vi) 101,000 349,920 The Company received $ 137,500 The Company has issued shares of common stock to providers of consulting services which are reported in the Consolidated Statements of Stockholders’ Equity. The value of these shares is reported as a prepaid expense and are amortized to expense over the contractual life of the respective consulting agreements. The amortization of stock issued for services as reported in the Consolidated Statements of Cash Flows was $ 442,559 399,840 Time-Based Restricted Stock Units We have granted time-based restricted stock units to certain participants under the Amended Plan that are stock-settled with common shares. Time-based restricted stock units granted under the Amended Plan vest over three years. Total stock-based compensation expense included in the Consolidated Statements of Operations and Consolidated Statements of Cash Flows was $ 2,109,783 1,462,768 667,668 606,014 56,000 .5 Our time-based restricted stock unit activity for the year ended March 31, 2024, was as follows: SCHEDULE OF TIME BASED RESTRICTED STOCK UNITS Units Outstanding Weighted Aggregate Balance at March 31, 2022 372,668 $ 4.07 $ 760,243 Granted 60,600 2.89 - Vested (177,184 ) 3.99 - Balance at March 31, 2023 256,084 3.85 643,209 Vested (198,584 ) 3.82 - Cancelled (25,500 ) 3.77 Balance at March 31, 2024 32,000 $ 4.08 $ 32,000 1) The aggregate intrinsic value of restricted stock units outstanding was based on our closing stock price on the last trading day of the period. Stock Options Stock options issued to employees typically vest over three years seven years 2,109,783 1,462,768 1,102,522 662,429 1,087,401 1.6 The fair value of each option grant is estimated on the date of grant using the Black-Scholes option pricing model. Annually, we make predictive assumptions regarding future stock price volatility, dividend yield, expected term and forfeiture rate. The dividend yield assumption is based on expected annual dividend yield on a grant date. To date, no dividends on common stock have been paid by us. Expected volatility for grants is based on our average historical volatility over a similar period as the expected term assumption used for our options as the expected volatility. The risk-free interest rate is based on yields of U.S. Treasury securities with maturities similar to the expected term of the options for each option group. We use the “simplified method” to determine the expected term of the stock option grants. We utilize this method because we do not have sufficient public company exercise data in which to make a reasonable estimate. The following table sets forth the assumptions used to estimate fair values of our stock options granted: SCHEDULE OF ESTIMATED FAIR VALUE ASSUMPTION Year Ended March 31, 2024 Year Ended March 31, 2023 Expected term 6 7 Expected volatility 75.9 95.7 % 111.7 146.9 % Risk-free interest rate 3.46 4.52 % 2.96 4.35 % Expected dividend yield 0 % 0 % Fair value on the date of grant $ 1.20 2.75 $ 1.87 2.79 Our stock option activity for the years ended March 31, 2024 and 2023 was as follows: SCHEDULE OF STOCK OPTION ACTIVITY Options Outstanding Weighted- (1) Weighted- Aggregate (2) Balance at March 31, 2022 195,000 $ 1.56 6.9 $ 100,200 Granted 714,849 2.37 Cancelled (25,000 ) 2.46 Balance at March 31, 2023 884,849 2.19 6.3 $ 307,750 Granted 822,605 1.77 Cancelled (198,332 ) 2.03 Balance at March 31, 2024 1,509,122 $ 1.98 5.7 $ — Options exercisable at March 31, 2024 572,415 (1) The exercise price of each option granted during the period shown above was equal to the market price of the underlying stock on the date of grant. (2) The aggregate intrinsic value of stock options outstanding was based on our closing stock price on the last trading day of this period. The closing stock price at the end of the period (March 31, 2024) was $ 1.07 Stock options granted for the year ended March 31, 2024 and 2023 were to employees and directors. The fair value of these options on the date of grant was $ 1,107,799 984,552 Options exercisable at March 31, 2024, had exercise prices ranging from $ 1.39 2.79 The following summarizes additional information about our stock options: SCHEDULE OF ADDITIONAL INFORMATION ABOUT STOCK OPTIONS Year Ended March 31, 2024 Year Ended March 31, 2023 Number of: Non-vested options, beginning of period 709,394 195,000 Non-vested options, end of period 936,707 709,394 Vested options, end of period 572,415 175,455 Year Ended March 31, 2024 Year Ended March 31, 2023 Weighted-average grant date fair value of: Non-vested options, beginning of period $ 2.23 $ 1.56 Non-vested options, end of period $ 1.84 $ 2.23 Vested options, end of period $ 2.21 $ 2.01 Forfeited options, during the period $ 2.03 $ - Warrants During the year ended March 31, 2024 the Company issued warrants to purchase an aggregate of 4,386,463 i) 1,200,002 1,273,365 ii) 385,000 463,476 iii) 300,000 234,741 iv) 80,000 87,485 v) 352,224 vi) 430,000 vii) 1,639,237 These warrants’ values were arrived at by using the Black-Scholes valuation model with the following assumptions: SCHEDULE OF WARRANT’S USING BLACK-SCHOLES VALUATION Year Ended March 31, 2024 Stock price on valuation date $ 1.07 2.15 Exercise price $ 1.20 2.75 Term (years) 2.0 3.0 Volatility 75.9 95.7 % Risk-free rate 3.46 4.52 % A summary of warrant activity for the years ended March 31, 2024, and 2023 is as follows: SCHEDULE OF WARRANT ACTIVITY Number of Weighted- Warrants Weighted- Outstanding, March 31, 2022 3,757,484 $ 4.95 3,693,734 $ 5.00 Exercised for cash (48,664 ) (1.36 ) Granted and issued - - Cashless warrant exercises - - Expired (146,003 ) (3.70 ) Outstanding, March 31, 2023 3,562,817 5.05 3,540,317 5.07 Granted and issued 4,386,463 1.80 Cashless warrant exercises (63,584 ) (1.34 ) Expired (16,750 ) (4.18 ) Outstanding, March 31, 2024 7,768,946 $ 3.29 7,768,946 $ 3.28 On March 31, 2024, the range of warrant prices for shares under warrants and the weighted-average remaining contractual life is as follows: SCHEDULE OF RANGE OF WARRANT PRICES Warrants Outstanding Warrants Exercisable Range of Warrant Exercise Price Number of Warrants Weighted- Average Price Weighted- Average Remaining Contractual (Years) Number of Warrants Weighted- Average Exercise Price $ 1.20 2.00 4,189,952 $ 1.63 2.80 635,713 $ 1.43 2.01 4.00 535,438 2.54 1.48 396,268 2.50 4.01 5.63 3,043,556 5.63 2.61 3,043,556 5.63 Total 7,768,946 $ 3.29 2.54 4,075,537 $ 4.67 Total stock-based compensation expense included in the Consolidated Statements of Operations and Consolidated Statements of Cash Flows was $ 2,109,783 and $ 1,462,768 for the years ended March 31, 2024, and 2023, respectively, of which warrants were $ 339,644 and $ 41,662 for the year ended March 31, 2024 and 2023, respectively. At March 31, 2024, there was no future unrecognized warrant expense.

INCOME TAXES

INCOME TAXES	12 Months Ended
	Mar. 31, 2024
Income Tax Disclosure [Abstract]
INCOME TAXES	NOTE 13 – INCOME TAXES The following table presents the net deferred tax assets as of March 31, 2024 and 2023: SCHEDULE OF DEFERRED TAX 2024 2023 Net operating loss carryforwards $ 10,786,000 8,311,000 Stock compensation 1,539,000 933,000 Other 74,000 118,000 Total deferred tax assets 12,399,000 9,362,000 Valuation allowance (12,399,000 ) (9,362,000 ) Net deferred tax assets $ — $ — Current income taxes are based upon the year’s income taxable for federal and state tax reporting purposes. Deferred income taxes (benefits) are provided for certain income and expenses, which are recognized in different periods for tax and financial reporting purposes. Deferred tax assets and liabilities are computed for differences between the financial statements and tax bases of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the period in which the differences are expected to affect taxable income. The Company’s deferred income taxes arise from the temporary differences between financial statement and income tax recognition of net operating losses. These loss carryovers would be limited under the Internal Revenue Code should a significant change in ownership occur within a three-year period. At March 31, 2024 and 2023, respectively, the Company had net operating loss carryforwards of approximately $ 37,500,000 29,000,000 10,786,000 8,311,000 3,037,000 1,613,000 Of the approximately $ 37,500,000 7,000,000 7,000,000 Income tax expense (benefit) to the statutory rate of 21% for the years ended March 31, 2024, and 2023 is as follows: SCHEDULE OF EFFECTIVE INCOME TAX RATE RECONCILIATION 2024 2023 Tax benefits at statutory rate 21.0 % 21.0 % State income tax benefit, net of federal 7.7 % 7.7 % Gross Effective Rate 28.7 % 28.7 % Valuation allowance (28.7 %) (28.7 %) Net effective rate - - The Company’s continuing practice is to recognize interest and/or penalties related to income tax matters in income tax expense. As of March 31, 2024 and 2023, the Company had no The Company is subject to taxation in the U.S. and Minnesota. Our tax years for 2020 and forward are subject to examination by tax authorities. The Company is not currently under examination by any tax authority. Management has evaluated tax positions in accordance with FASB ASC 740, and has not identified any tax positions, other than those discussed above, that require disclosure.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Mar. 31, 2024
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 14 – SUBSEQUENT EVENTS From April 1, 2024, through the date of this annual report 10K filing, the Company sold 1,889,434 1,889,434 .70 1,889,434 1.50 three years 1,322,600 On April 15, 2024, the company issued a restricted stock bonus of 150,000 90,000 On April 29, 2024, the company converted $ 300,000 1,558 430,798 430,798 .70 430,798 1.50 three years From April 10, 2024, through May 15, 2024, the company issued an aggregate of 376,000 201,912

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION (Policies)	12 Months Ended
	Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Description	(A) Organization and Description The Company is in the business of licensing and commercializing our proprietary medical devices and biomaterials for the treatment and/or management of afflictions and diseases in animals, initially for dogs and horses. The Company began commercialization of its lead product Spryng™ with OsteoCushion™ Technology, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions such as osteoarthritis in dogs and horses in September 2021. The Company has a pipeline of additional products for the treatment of animals in various stages of development. A portfolio of nineteen patents protects the Company’s biomaterials, products, production processes and methods of use. The Company’s operations are conducted from its headquarter facilities in suburban Minneapolis, Minnesota.
Basis of Presentation	(B) Basis of Presentation PetVivo Holdings, Inc. (the “Company”) was incorporated in Nevada under a former name in 2009 and entered its current business in 2014 through a stock exchange reverse merger with PetVivo, Inc., a Minnesota corporation. This merger resulted in PetVivo, Inc. becoming a wholly-owned subsidiary of the Company. In April 2017, the Company acquired another Minnesota corporation, Gel-Del Technologies, Inc., through a statutory merger, which is also a wholly-owned subsidiary of the Company.
Principles of Consolidation	(C) Principles of Consolidation The accompanying consolidated financial statements include the accounts of the Company and its two wholly-owned Minnesota corporations, Gel-Del Technologies, Inc. and PetVivo, Inc. All intercompany accounts have been eliminated during consolidation.
Use of Estimates	(D) Use of Estimates In preparing financial statements in conformity with generally accepted accounting principles, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include collectability of accounts receivable, inventory obsolescence, estimated useful lives and potential impairment of property and equipment and intangibles, estimate of fair value of share-based payments, distributor rebate payable, provision for product returns, right of use lease assets and liabilities and valuation of deferred tax assets.
Cash and Cash Equivalents	(E) Cash and Cash Equivalents The Company considers all highly-liquid, temporary cash investments with original maturity of three months or less to be cash equivalents. The Company had no
Concentration Risk	(F) Concentration Risk The Company maintains its cash with various financial institutions, which at times may exceed federally insured limits. At March 31, 2024 and 2023, the Company did not have cash balances in excess of the federally insured limits.
Accounts Receivable	(G) Accounts Receivable Accounts receivable consists primarily of amounts due from a distributor (see revenue recognition). Accounts receivable is recorded based on management’s assessment of the expected consideration to be received, based on a detailed review of historical collections. Management relies on the results of the assessment, which includes payment history of the applicable payer as a primary source of information in estimating the collectability of our accounts receivable as well as a forecast of projected credit losses. We update our assessment on a quarterly basis, which to date has not resulted in any material adjustments to the valuation of our accounts receivable since all receivables to date have been collected. We believe the assessment provides reasonable estimates of our accounts receivable valuation, and therefore we believe that substantially all accounts receivable are fully collectible. Accordingly, as of March 31, 2024 and 2023, our allowance for credit losses was zero In fiscal 2023, the Company has adopted an accounting standard: Adoption of ASC 326, Financial Instruments - Credit Losses, which amends the impairment model by requiring entities to use a forward-looking approach to estimate lifetime expected credit losses on certain types of financial instruments, including trade receivables
Inventory	(H) Inventory Inventories are recorded in accordance with Accounting Standards Codification (“ASC”) 330, Inventory, and are stated at the lower of cost or net realizable value. We account for inventories using the first in first out (“FIFO”) methodology. Provisions for inventory obsolescence are charged to Cost of Sales. There were no
Property & Equipment	(I) Property & Equipment Property and equipment are recorded at cost. Expenditures for major additions and betterments are capitalized. Maintenance and repairs are charged to operations as incurred. Depreciation is computed by the straight-line method (after considering their respective estimated residual values) over the assets estimated useful life of 3 5 5 7
Patents and Trademarks	(J) Patents and Trademarks The Company capitalizes direct costs for the maintenance and advancement of their patents and trademarks and amortizes these costs over the lesser of the useful life of 60
Loss Per Share	(K) Loss Per Share Basic loss per share is computed by dividing net loss by weighted average number of shares of common stock outstanding during each period. Diluted loss per share is computed by dividing net loss by the weighted average number of shares of common stock, common stock equivalents and potentially dilutive securities outstanding during the period. The Company had 7,768,946 1.20 6.67 3.29 The Company had 32,000 The Company had 1,509,122 1.39 2.79 1.98 The Company had 3,562,817 1.20 5.63 5.05 The Company had 256,804 The Company had 884,849 1.39 2.79 2.19 The Company uses the guidance in Accounting Standards Codification (“ASC”) 260 to determine if-converted loss per share. ASC 260 states that convertible securities should be considered exercised on the latter of the first day of the reporting period’s quarter or the inception date of the debt instrument. Also, the if-converted method shall not be applied for the purposes of computing diluted EPS if the effect would be anti-dilutive.
Revenue Recognition	(L) Revenue Recognition The Company recognizes revenue in accordance with ASC 606 “Revenue from Contracts with Customers.” The Company derives revenue from the sale of its pet care products directly to its veterinarian customers in the United States. The Company recognizes revenue when performance obligations under the terms of a contract with the veterinarian customer are satisfied. Product sales occur once control or title is transferred based on the commercial terms. Revenue is recognized upon delivery to the customer, which is when control of these products is transferred and in an amount that reflects the consideration the Company expects to receive for these products. Shipping costs charged to customers are reported as an offset to the respective shipping costs. The Company does not have any significant financing components as payment is received at or shortly after the point of sale. The Company entered into a Distribution Services Agreement (the “Agreement”) with MWI Veterinary Supply Co. (the “Distributor”) on June 17, 2022. Contracts with the Distributor are evidenced by individual executed purchase orders subject to the terms of the Agreement. The contracts consist of a single performance obligation related to the sale of our pet care products. Product sales occur once control or title is transferred based on the commercial terms in the Agreement. Revenue is recognized upon delivery to the Distributor; payment is due within 60 days. The Agreement provides for a distribution fee payable to the Distributor equal to 5 For the year ended March 31, 2024 and 2023, the Company recognized revenue from product sales under the Agreement of $ 626,176 636,345 65 69 Assets and liabilities (included in accrued expenses) under the Agreement were as follows: SCHEDULE OF RECOGNIZED REVENUE ASSETS AND LIABILITIES March 31, 2024 March 31, 2023 Accounts receivable $ 18,669 $ 81,510 Rebate liability 57,264 28,000 Distribution fee payable 7,583 5,187 The Company entered into a Distribution Services Agreement (the “Agreement”) with Covetrus North America LLC (“Covetrus”) on December 18, 2023. Contracts with Covetrus are evidenced by individual executed purchase orders subject to the terms of the Agreement. The contracts consist of a single performance obligation related to the sale of our pet care products. Product sales occur once control or title is transferred based on the commercial terms in the Agreement. Revenue is recognized upon delivery to the Distributor; payment is due within 60 days. The Agreement provides for a rebate payable to the Distributor based on annual sales volume that is retroactively applied. The rebate is estimated under the expected value method and is netted against revenue. Sales are subject to various right of return provisions; the Company uses an expected value method to estimate returns and has determined that any returns would be immaterial as of March 31, 2024. As a result, there is no return liability recorded. Shipping and handling costs are a fulfillment activity and are reported as cost of sales. For the year ended March 31, 2024, the Company recognized revenue from product sales to Covetrus of $ 105,637 11 no
Research and Development	(M) Research and Development The Company expenses research and development costs as incurred.
Fair Value of Financial Instruments	(N) Fair Value of Financial Instruments The Company applies the accounting guidance under ASC 820-10, “Fair Value Measurements”, as well as certain related Financial Accounting Standards Board (“FASB”) staff positions. This guidance defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact business and considers assumptions that marketplace participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance. The guidance also establishes a fair value hierarchy for measurements of fair value as follows: ● Level 1 - quoted market prices in active markets for identical assets or liabilities. ● Level 2 - inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. ● Level 3 - unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The Company’s financial instruments consist of accounts receivable, accounts payable, accrued expenses and note payable and accrued interest. The carrying amount of the Company’s financial instruments approximates their fair value as of March 31, 2024, and March 31, 2023, due to the short-term nature of these instruments and the Company’s borrowing rate of interest. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability. The valuation of the Company’s note recorded at fair value is determined using Level 3 inputs, which consider (i) time value, (ii) current market, and (iii) contractual prices. The Company had no
Stock-Based Compensation	(O) Stock-Based Compensation Stock-based compensation is accounted for based on the requirements of ASC 718 – “Compensation – Stock Compensation” which requires recognition in the financial statements of the cost of employee, director, and non-employee services received in exchange for an award of equity instruments over the period the employee, director, or non-employee is required to perform the services in exchange for the award (presumptively, the vesting period). The ASC also requires measurement of the cost of employee, director, and non-employee services received in exchange for an award based on grant-date fair value of the award. The Company has elected to recognize forfeitures as they occur as permitted under Accounting Standards Update (“ASU”) 2016-09 Improvements to Employee Share-Based Payment.
Income Taxes	(P) Income Taxes The Company accounts for income taxes under ASC 740. Deferred tax assets and liabilities are determined based upon differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. As required by ASC 450, the Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority. The Company is not currently under examination by any federal or state jurisdiction. The Company’s policy is to record tax-related interest and penalties as a component of operating expenses.
Recent Accounting Pronouncements	(Q) Recent Accounting Pronouncements The Company has reviewed the FASB issued ASU accounting pronouncements and interpretations thereof that have effectiveness dates during the periods reported and in future periods. The Company has carefully considered the new pronouncements that alter previous generally accepted accounting principles and does not believe that any new or modified principles will have a material impact on the Company’s reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of the Company’s financial management. In August 2020, the FASB issued ASU 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40) - Accounting for Convertible Instruments and Contracts on an Entity’s Own Equity. The ASU simplifies accounting for convertible instruments by removing major separation models required under current GAAP. Consequently, more convertible debt instruments will be reported as a single liability instrument with no separate accounting for embedded conversion features. The ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception, which will permit more equity contracts to qualify for the exceptions. The ASU also simplifies the diluted net income per share calculation in certain areas. The new guidance is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years, and early adoption is permitted. The Company is currently evaluating the impact of the adoption of the standard on the consolidated financial statements. In June 2016, the FASB issued ASU 2016-13, “Financial Instruments-Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments,” which replaces the existing “incurred loss” model for recognizing credit losses with an “expected loss” model referred to as the CECL model. Under the CECL model, the Company is required to present certain financial assets carried at amortized cost, such as accounts receivable, at the net amount expected to be collected. The measurement of expected credit losses is based on information about past events, including historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. The Company adopted this standard in the consolidated financial statements for the twelve months ended March 31, 2024. The change had no impact on the Company’s financial statements. We believe the critical accounting policies (Item 7 Management’s Discussion and Analysis of Financial Condition and Results of Operation) involve the most significant judgments and estimates used in the preparation of the consolidated financial statements. All other newly issued but not yet effective accounting pronouncements have been deemed either immaterial or not applicable.

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION (Tables)	12 Months Ended
	Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
SCHEDULE OF RECOGNIZED REVENUE ASSETS AND LIABILITIES	Assets and liabilities (included in accrued expenses) under the Agreement were as follows: SCHEDULE OF RECOGNIZED REVENUE ASSETS AND LIABILITIES March 31, 2024 March 31, 2023 Accounts receivable $ 18,669 $ 81,510 Rebate liability 57,264 28,000 Distribution fee payable 7,583 5,187

INVENTORY (Tables)

INVENTORY (Tables)	12 Months Ended
	Mar. 31, 2024
Inventory Disclosure [Abstract]
SCHEDULE OF INVENTORY	The inventory components are as follows: SCHEDULE OF INVENTORY March 31, 2024 March 31, 2023 Finished goods $ 35,442 $ 13,159 Work in process 20,289 53,398 Raw materials 334,345 303,726 Total Net $ 390,076 $ 370,283

PREPAID EXPENSES AND OTHER AS_2

PREPAID EXPENSES AND OTHER ASSETS (Tables)	12 Months Ended
	Mar. 31, 2024
Prepaid Expenses And Other Assets
SCHEDULE OF PREPAID EXPENSES AND OTHER ASSETS	The table below shows our prepaid expenses and other assets for the periods ending March 31, 2024 and 2023. SCHEDULE OF PREPAID EXPENSES AND OTHER ASSETS March 31, 2024 March 31, 2023 Investor relations services $ 217,000 $ 115,000 Insurance 138,000 130,000 Nasdaq and FINRA fees 67,000 63,000 Trade shows 44,000 42,000 Consulting 26,000 56,000 Rent 25,000 20,000 Software subscription fees 20,000 19,000 Supplier advance - 42,000 Other 8,512 4,694 Total $ 545,512 $ 491,694

PROPERTY AND EQUIPMENT (Tables)

PROPERTY AND EQUIPMENT (Tables)	12 Months Ended
	Mar. 31, 2024
Property, Plant and Equipment [Abstract]
SCHEDULE OF PROPERTY AND EQUIPMENT	The components of property and equipment were as follows: SCHEDULE OF PROPERTY AND EQUIPMENT March 31, 2024 March 31, 2023 Leasehold improvements $ 418,041 $ 216,159 Production equipment 661,204 577,067 R&D equipment 25,184 25,184 Computer equipment and furniture 144,817 121,732 Total, at cost 1,249,246 940,142 Accumulated depreciation (427,590 ) (309,290 ) Total Net $ 821,656 $ 630,852

PATENTS AND TRADEMARKS (Tables)

PATENTS AND TRADEMARKS (Tables)	12 Months Ended
	Mar. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
SCHEDULE OF COMPONENTS OF PATENTS AND TRADEMARKS	The components of patents and trademarks, all of which are finite-lived, were as follows: SCHEDULE OF COMPONENTS OF PATENTS AND TRADEMARKS March 31, 2024 March 31, 2023 Patents $ 3,870,057 $ 3,870,057 Trademarks 26,142 26,142 Total at cost 3,896,199 3,896,199 Accumulated Amortization (3,866,100 ) (3,857,550 ) Total net $ 30,099 $ 38,649

ACCRUED EXPENSES (Tables)

ACCRUED EXPENSES (Tables)	12 Months Ended
	Mar. 31, 2024
Payables and Accruals [Abstract]
SCHEDULE OF COMPONENTS OF ACCRUED EXPENSES	The components of accrued expenses were as follows: SCHEDULE OF COMPONENTS OF ACCRUED EXPENSES March 31, 2024 March 31, 2023 Accrued payroll and related taxes $ 111,353 $ 258,978 Accrued expenses 131,677 188,666 Accrued lease termination expense - 332,238 Total $ 243,030 $ 779,882

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Tables)	12 Months Ended
	Mar. 31, 2024
Commitments and Contingencies Disclosure [Abstract]
SCHEDULE OF MATURITY OF ANNUAL UNDISCOUNTED OPERATING LEASE LIABILITY	The following is a maturity analysis of the approximate annual undiscounted cash flows of the operating lease liabilities as of March 31, 2024: SCHEDULE OF MATURITY OF ANNUAL UNDISCOUNTED OPERATING LEASE LIABILITY 2024 $ 41,000 2025 222,000 2026 226,000 2027 180,000 2028 114,000 2029 114,000 Thereafter 519,000 Total 1,416,000 Less: amount representing interest (222,000 ) Total $ 1,194,000
SCHEDULE OF BASE RENT LEASE PAYMENTS	SCHEDULE OF BASE RENT LEASE PAYMENTS Present value of future base rent lease payments $ 1,194,348 Base rent payments included in prepaid expenses - Present value of future base rent lease payments – net $ 1,194,348
SCHEDULE OF LEASE CURRENT AND NON-CURRENT ASSETS AND LIABILITIES	As of March 31, 2024, the present value of future base rent lease payments – net is classified between current and non-current assets and liabilities as follows: SCHEDULE OF LEASE CURRENT AND NON-CURRENT ASSETS AND LIABILITIES Operating lease right-of-use asset $ 1,194,348 Total operating lease assets 1,194,348 Operating lease current liability 190,589 Operating lease non-current liability 1,003,759 Total operating lease liabilities $ 1,194,348

STOCKHOLDERS_ EQUITY (Tables)

STOCKHOLDERS’ EQUITY (Tables)	12 Months Ended
	Mar. 31, 2024
Equity [Abstract]
SCHEDULE OF TIME BASED RESTRICTED STOCK UNITS	Our time-based restricted stock unit activity for the year ended March 31, 2024, was as follows: SCHEDULE OF TIME BASED RESTRICTED STOCK UNITS Units Outstanding Weighted Aggregate Balance at March 31, 2022 372,668 $ 4.07 $ 760,243 Granted 60,600 2.89 - Vested (177,184 ) 3.99 - Balance at March 31, 2023 256,084 3.85 643,209 Vested (198,584 ) 3.82 - Cancelled (25,500 ) 3.77 Balance at March 31, 2024 32,000 $ 4.08 $ 32,000 1) The aggregate intrinsic value of restricted stock units outstanding was based on our closing stock price on the last trading day of the period.
SCHEDULE OF ESTIMATED FAIR VALUE ASSUMPTION	The following table sets forth the assumptions used to estimate fair values of our stock options granted: SCHEDULE OF ESTIMATED FAIR VALUE ASSUMPTION Year Ended March 31, 2024 Year Ended March 31, 2023 Expected term 6 7 Expected volatility 75.9 95.7 % 111.7 146.9 % Risk-free interest rate 3.46 4.52 % 2.96 4.35 % Expected dividend yield 0 % 0 % Fair value on the date of grant $ 1.20 2.75 $ 1.87 2.79
SCHEDULE OF STOCK OPTION ACTIVITY	Our stock option activity for the years ended March 31, 2024 and 2023 was as follows: SCHEDULE OF STOCK OPTION ACTIVITY Options Outstanding Weighted- (1) Weighted- Aggregate (2) Balance at March 31, 2022 195,000 $ 1.56 6.9 $ 100,200 Granted 714,849 2.37 Cancelled (25,000 ) 2.46 Balance at March 31, 2023 884,849 2.19 6.3 $ 307,750 Granted 822,605 1.77 Cancelled (198,332 ) 2.03 Balance at March 31, 2024 1,509,122 $ 1.98 5.7 $ — Options exercisable at March 31, 2024 572,415 (1) The exercise price of each option granted during the period shown above was equal to the market price of the underlying stock on the date of grant. (2) The aggregate intrinsic value of stock options outstanding was based on our closing stock price on the last trading day of this period. The closing stock price at the end of the period (March 31, 2024) was $ 1.07
SCHEDULE OF ADDITIONAL INFORMATION ABOUT STOCK OPTIONS	The following summarizes additional information about our stock options: SCHEDULE OF ADDITIONAL INFORMATION ABOUT STOCK OPTIONS Year Ended March 31, 2024 Year Ended March 31, 2023 Number of: Non-vested options, beginning of period 709,394 195,000 Non-vested options, end of period 936,707 709,394 Vested options, end of period 572,415 175,455 Year Ended March 31, 2024 Year Ended March 31, 2023 Weighted-average grant date fair value of: Non-vested options, beginning of period $ 2.23 $ 1.56 Non-vested options, end of period $ 1.84 $ 2.23 Vested options, end of period $ 2.21 $ 2.01 Forfeited options, during the period $ 2.03 $ -
SCHEDULE OF WARRANT’S USING BLACK-SCHOLES VALUATION	These warrants’ values were arrived at by using the Black-Scholes valuation model with the following assumptions: SCHEDULE OF WARRANT’S USING BLACK-SCHOLES VALUATION Year Ended March 31, 2024 Stock price on valuation date $ 1.07 2.15 Exercise price $ 1.20 2.75 Term (years) 2.0 3.0 Volatility 75.9 95.7 % Risk-free rate 3.46 4.52 %
SCHEDULE OF WARRANT ACTIVITY	A summary of warrant activity for the years ended March 31, 2024, and 2023 is as follows: SCHEDULE OF WARRANT ACTIVITY Number of Weighted- Warrants Weighted- Outstanding, March 31, 2022 3,757,484 $ 4.95 3,693,734 $ 5.00 Exercised for cash (48,664 ) (1.36 ) Granted and issued - - Cashless warrant exercises - - Expired (146,003 ) (3.70 ) Outstanding, March 31, 2023 3,562,817 5.05 3,540,317 5.07 Granted and issued 4,386,463 1.80 Cashless warrant exercises (63,584 ) (1.34 ) Expired (16,750 ) (4.18 ) Outstanding, March 31, 2024 7,768,946 $ 3.29 7,768,946 $ 3.28
SCHEDULE OF RANGE OF WARRANT PRICES	On March 31, 2024, the range of warrant prices for shares under warrants and the weighted-average remaining contractual life is as follows: SCHEDULE OF RANGE OF WARRANT PRICES Warrants Outstanding Warrants Exercisable Range of Warrant Exercise Price Number of Warrants Weighted- Average Price Weighted- Average Remaining Contractual (Years) Number of Warrants Weighted- Average Exercise Price $ 1.20 2.00 4,189,952 $ 1.63 2.80 635,713 $ 1.43 2.01 4.00 535,438 2.54 1.48 396,268 2.50 4.01 5.63 3,043,556 5.63 2.61 3,043,556 5.63 Total 7,768,946 $ 3.29 2.54 4,075,537 $ 4.67

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Mar. 31, 2024
Income Tax Disclosure [Abstract]
SCHEDULE OF DEFERRED TAX	The following table presents the net deferred tax assets as of March 31, 2024 and 2023: SCHEDULE OF DEFERRED TAX 2024 2023 Net operating loss carryforwards $ 10,786,000 8,311,000 Stock compensation 1,539,000 933,000 Other 74,000 118,000 Total deferred tax assets 12,399,000 9,362,000 Valuation allowance (12,399,000 ) (9,362,000 ) Net deferred tax assets $ — $ —
SCHEDULE OF EFFECTIVE INCOME TAX RATE RECONCILIATION	Income tax expense (benefit) to the statutory rate of 21% for the years ended March 31, 2024, and 2023 is as follows: SCHEDULE OF EFFECTIVE INCOME TAX RATE RECONCILIATION 2024 2023 Tax benefits at statutory rate 21.0 % 21.0 % State income tax benefit, net of federal 7.7 % 7.7 % Gross Effective Rate 28.7 % 28.7 % Valuation allowance (28.7 %) (28.7 %) Net effective rate - -

SCHEDULE OF RECOGNIZED REVENUE

SCHEDULE OF RECOGNIZED REVENUE ASSETS AND LIABILITIES (Details) - USD ($)	Mar. 31, 2024	Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accounts receivable	$ 18,669	$ 81,510
Rebate liability	57,264	28,000
Distribution fee payable	$ 7,583	$ 5,187

SUMMARY OF SIGNIFICANT ACCOUN_4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION (Details Narrative) - USD ($)	12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Cash equivalents	$ 0
Allowance for credit losses	0	$ 0
Provisions for inventory obsolescence	$ 0	0
Monthly sales gross percentage	5%
Revenue from contract with customer	$ 968,706	917,162
Fair value, net asset (liability)	0	0
Product [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue from contract with customer	$ 626,176	$ 636,345
Percentage of net revenue	65%	69%
Sales To Convetrus [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue from contract with customer	$ 105,637
Percentage of net revenue	11%
Accounts receivable net	$ 0
Warrant [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Antidilutive securities excluded from computation of earnings per share amount	7,768,946	3,562,817
Restricted Stock Units (RSUs) [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Antidilutive securities excluded from computation of earnings per share amount	32,000	256,804
Share-Based Payment Arrangement, Option [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Antidilutive securities excluded from computation of earnings per share amount	1,509,122	884,849
Patents and Trademarks [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Estimated useful life of intangible assets	60 months
Minimum [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Weighted average, exercise price	$ 1.20	$ 1.87
Minimum [Member] | Warrant [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Weighted average, exercise price	1.20	1.20
Minimum [Member] | Share-Based Payment Arrangement, Option [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Weighted average, exercise price	1.39	1.39
Maximum [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Weighted average, exercise price	2.75	2.79
Maximum [Member] | Warrant [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Weighted average, exercise price	6.67	5.63
Maximum [Member] | Share-Based Payment Arrangement, Option [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Weighted average, exercise price	2.79	2.79
Weighted Average [Member] | Warrant [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Weighted average, exercise price	3.29	5.05
Weighted Average [Member] | Share-Based Payment Arrangement, Option [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Weighted average, exercise price	$ 1.98	$ 2.19
Production and Computer Equipment and Furniture [Member] | Minimum [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Estimated useful life of assets	3 years
Production and Computer Equipment and Furniture [Member] | Maximum [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Estimated useful life of assets	5 years
Leasehold Improvements [Member] | Minimum [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Estimated useful life of assets	5 years
Leasehold Improvements [Member] | Maximum [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Estimated useful life of assets	7 years

SCHEDULE OF INVENTORY (Details)

SCHEDULE OF INVENTORY (Details) - USD ($)	Mar. 31, 2024	Mar. 31, 2023
Inventory Disclosure [Abstract]
Finished goods	$ 35,442	$ 13,159
Work in process	20,289	53,398
Raw materials	334,345	303,726
Total Net	$ 390,076	$ 370,283

INVENTORY (Details Narrative)

INVENTORY (Details Narrative) - USD ($)	Mar. 31, 2024	Mar. 31, 2023
Inventory Disclosure [Abstract]
Inventory	$ 390,076	$ 370,283

SCHEDULE OF PREPAID EXPENSES AN

SCHEDULE OF PREPAID EXPENSES AND OTHER ASSETS (Details) - USD ($)	Mar. 31, 2024	Mar. 31, 2023
Prepaid Expenses And Other Assets
Investor relations services	$ 217,000	$ 115,000
Insurance	138,000	130,000
Nasdaq and FINRA fees	67,000	63,000
Trade shows	44,000	42,000
Consulting	26,000	56,000
Rent	25,000	20,000
Software subscription fees	20,000	19,000
Supplier advance		42,000
Other	8,512	4,694
Total	$ 545,512	$ 491,694

SCHEDULE OF PROPERTY AND EQUIPM

SCHEDULE OF PROPERTY AND EQUIPMENT (Details) - USD ($)	Mar. 31, 2024	Mar. 31, 2023
Property, Plant and Equipment [Line Items]
Total, at cost	$ 1,249,246	$ 940,142
Accumulated depreciation	(427,590)	(309,290)
Total Net	821,656	630,852
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Total, at cost	418,041	216,159
Equipment [Member]
Property, Plant and Equipment [Line Items]
Total, at cost	661,204	577,067
R&D Equipment [Member]
Property, Plant and Equipment [Line Items]
Total, at cost	25,184	25,184
Computer Equipment and Furniture [Member]
Property, Plant and Equipment [Line Items]
Total, at cost	$ 144,817	$ 121,732

PROPERTY AND EQUIPMENT (Details

PROPERTY AND EQUIPMENT (Details Narrative) - USD ($)	12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 118,300	$ 104,631

SCHEDULE OF COMPONENTS OF PATEN

SCHEDULE OF COMPONENTS OF PATENTS AND TRADEMARKS (Details) - USD ($)	Mar. 31, 2024	Mar. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Patents	$ 3,870,057	$ 3,870,057
Trademarks	26,142	26,142
Total at cost	3,896,199	3,896,199
Accumulated Amortization	(3,866,100)	(3,857,550)
Total net	$ 30,099	$ 38,649

PATENTS AND TRADEMARKS (Details

PATENTS AND TRADEMARKS (Details Narrative) - USD ($)	12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization expense	$ 8,550	$ 9,803

SCHEDULE OF COMPONENTS OF ACCRU

SCHEDULE OF COMPONENTS OF ACCRUED EXPENSES (Details) - USD ($)	Mar. 31, 2024	Mar. 31, 2023
Payables and Accruals [Abstract]
Accrued payroll and related taxes	$ 111,353	$ 258,978
Accrued expenses	131,677	188,666
Accrued lease termination expense		332,238
Total	$ 243,030	$ 779,882

ACCRUED EXPENSES (Details Narra

ACCRUED EXPENSES (Details Narrative) - USD ($)	12 Months Ended
	Mar. 31, 2024	Mar. 31, 2018
Payables and Accruals [Abstract]
Lease termination liability payable		$ 332,238
Accounts payable	$ 53,636
Extinguishment of debt	$ 385,874

NOTE PAYABLE (Details Narrative

NOTE PAYABLE (Details Narrative) - USD ($)			1 Months Ended		12 Months Ended
	Apr. 29, 2024	Feb. 05, 2024	Feb. 29, 2024	Oct. 31, 2023	Mar. 31, 2024	Apr. 10, 2024	Apr. 01, 2024	Feb. 02, 2024	Mar. 31, 2023	Jan. 31, 2020
Short-Term Debt [Line Items]
Notes payable				$ 120,000	$ 20,528				$ 27,351	$ 42,500
Debt instrument, interest rate, percentage				10%						6%
Notes payable, current liabilities					7,356				6,936
Notes payable other liabilities					13,171				$ 20,415
Debt instrument maturity date				February 2024
Common stock conversion basis				0.75
Conversion of convertible securities		$ 123,255			$ 700,755
Conversion of convertible securities shares		164,340
Debt instrument, convertible, conversion price			$ 0.75		$ 1.07
Accured interest			$ 3,255
Debt conversion converted shares issued			164,340
Warrants price per share								$ 1.50
Common Stock [Member]
Short-Term Debt [Line Items]
Conversion of convertible securities					$ 549
Conversion of convertible securities shares					549,340
Subsequent Event [Member]
Short-Term Debt [Line Items]
Debt instrument, convertible, conversion price	$ 0.70
Accured interest	$ 1,558
Debt conversion converted shares issued	430,798
Number of shares issued	430,798						1,889,434
Warrants price per share	$ 1.50						$ 1.50
Subsequent Event [Member] | Common Stock [Member]
Short-Term Debt [Line Items]
Debt conversion converted shares issued	430,798
Convertible Debt [Member]
Short-Term Debt [Line Items]
Debt instrument, interest rate, percentage					10%
Convertible promissory note					$ 150,000
Debt instrument, convertible, conversion price					$ 0.70
Convertible Debt [Member] | Subsequent Event [Member]
Short-Term Debt [Line Items]
Convertible promissory note						$ 150,000
Debt instrument face amount	$ 300,000					$ 300,000
Accured interest	$ 1,558
Number of shares issued	430,798
Warrants price per share	$ 1.50

RETIREMENT PLAN (Details Narrat

RETIREMENT PLAN (Details Narrative) - USD ($)	12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Retirement Benefits [Abstract]
Discretionary contributions	$ 51,441	$ 35,266

SCHEDULE OF MATURITY OF ANNUAL

SCHEDULE OF MATURITY OF ANNUAL UNDISCOUNTED OPERATING LEASE LIABILITY (Details)	Mar. 31, 2024 USD ($)
Commitments and Contingencies Disclosure [Abstract]
2024	$ 41,000
2025	222,000
2026	226,000
2027	180,000
2028	114,000
2029	114,000
Thereafter	519,000
Total	1,416,000
Less: amount representing interest	(222,000)
Total	$ 1,194,000

SCHEDULE OF BASE RENT LEASE PAY

SCHEDULE OF BASE RENT LEASE PAYMENTS (Details)	Mar. 31, 2024 USD ($)
Commitments and Contingencies Disclosure [Abstract]
Present value of future base rent lease payments	$ 1,194,348
Base rent payments included in prepaid expenses
Present value of future base rent lease payments – net	$ 1,194,348

SCHEDULE OF LEASE CURRENT AND N

SCHEDULE OF LEASE CURRENT AND NON-CURRENT ASSETS AND LIABILITIES (Details) - USD ($)	Mar. 31, 2024	Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Operating lease right-of-use asset	$ 1,194,348
Total operating lease assets	1,194,348	$ 317,981
Operating lease current liability	190,589	78,149
Operating lease non-current liability	1,003,759	$ 20,415
Total operating lease liabilities	$ 1,194,348

COMMITMENTS AND CONTINGENCIES_2

COMMITMENTS AND CONTINGENCIES (Details Narrative)		1 Months Ended				12 Months Ended
	Jan. 10, 2023 USD ($) ft²	Sep. 30, 2023 USD ($)	Jan. 31, 2022 ft²	Jan. 31, 2020 USD ($)	May 31, 2017 ft²	Mar. 31, 2024 USD ($)	Mar. 31, 2023 USD ($)	Oct. 31, 2023 USD ($)
Loss Contingencies [Line Items]
Operating lease term					84 months
Area of land | ft²					3,577
Annual increase in base rent, percentage					2%
Lease extension description						the extended lease terms to June 2026, November 2026, March 2027, and June 2033
Notes payable				$ 42,500		$ 20,528	$ 27,351	$ 120,000
Operating lease right use of asset						1,194,348	317,981
Operating lease liabilities						$ 1,194,000
Weighted average remaining lease term						4 years 8 months 12 days
Weighted average discount rate						4.15%
David Masters [Member]
Loss Contingencies [Line Items]
Legal settlement amount						$ 180,000
Settlement expense		$ 180,000
David Masters [Member] | Minimum [Member]
Loss Contingencies [Line Items]
Litigation reserve						$ 2,000,000
June 2026 [Member]
Loss Contingencies [Line Items]
Operating lease treasury rate						0.12%
November 2026 [Member]
Loss Contingencies [Line Items]
Operating lease treasury rate						0.40%
March 2027 [Member]
Loss Contingencies [Line Items]
Operating lease treasury rate						7.60%
June 2023 [Member]
Loss Contingencies [Line Items]
Operating lease treasury rate						4.39%
Vehicles [Member]
Loss Contingencies [Line Items]
Lease term						48 months
Operating lease right use of asset						$ 150,000
Operating lease expense						79,381	81,531
Extended Lease Term to 2026 [Member]
Loss Contingencies [Line Items]
Lease extension description				In January 2020, the Company entered into a lease amendment to extend the lease term through November of 2026
Notes payable				$ 42,500
Base rent						2,340	2,294
Operating lease liabilities						1,194,000
January 2022 Lease [Member]
Loss Contingencies [Line Items]
Operating lease term			63 months
Area of land | ft²			2,400
Annual increase in base rent, percentage			2.50%
Base rent						2,808	$ 2,740
January 10, 2023 Lease[Member]
Loss Contingencies [Line Items]
Area of land | ft²	14,000
Annual increase in base rent, percentage	2.50%
Base rent	$ 8,420					$ 8,420
Lease termination	The lease will terminate on June 30, 2033
Renewal term	5 years

GOING CONCERN (Details Narrativ

GOING CONCERN (Details Narrative) - USD ($)	12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net loss	$ 10,955,295	$ 8,717,608
Net cash used in operating activities	7,419,588	6,794,483
Accumulated deficit	$ 82,799,324	$ 71,844,029

SCHEDULE OF TIME BASED RESTRICT

SCHEDULE OF TIME BASED RESTRICTED STOCK UNITS (Details) - Restricted Stock Units (RSUs) [Member] - USD ($)		12 Months Ended
		Mar. 31, 2024	Mar. 31, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Time based RSU's, Balance		256,084	372,668
Time based RSU's, Weighted Average Grant Date Fair Value Per Unit		$ 3.85	$ 4.07
Aggregate Intrinsic Value, RSU's, Balance	[1]	$ 643,209	$ 760,243
Time based RSU's Granted			60,600
Time based RSU's, Weighted Average Grant Date Fair Value Per Unit, Granted			$ 2.89
Time based RSU's Vested		(198,584)	(177,184)
Time based RSU's, Weighted Average Vested Date Fair Value Per Unit, Vested		$ 3.82	$ 3.99
Time based RSU's Cancelled		(25,500)
Time based RSU's, Weighted Average Vested Date Fair Value Per Unit, Cancelled		$ 3.77
Time based RSU's, Balance		32,000	256,084
Time based RSU's, Weighted Average Grant Date Fair Value Per Unit		$ 4.08	$ 3.85
Aggregate Intrinsic Value, RSU's, Balance	[1]	$ 32,000	$ 643,209
[1]The aggregate intrinsic value of restricted stock units outstanding was based on our closing stock price on the last trading day of the period.

SCHEDULE OF ESTIMATED FAIR VALU

SCHEDULE OF ESTIMATED FAIR VALUE ASSUMPTION (Details) - $ / shares	12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Expected term	6 years	7 years
Expected volatility, minimum	75.90%	111.70%
Expected volatility, maximum	95.70%	146.90%
Risk-free interest rate, minimum	3.46%	2.96%
Risk-free interest rate, maximum	4.52%	4.35%
Expected dividend yield	0%	0%
Minimum [Member]
Fair value on the date of grant	$ 1.20	$ 1.87
Maximum [Member]
Fair value on the date of grant	$ 2.75	$ 2.79

SCHEDULE OF STOCK OPTION ACTIVI

SCHEDULE OF STOCK OPTION ACTIVITY (Details) - USD ($)		12 Months Ended
		Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2022
Equity [Abstract]
Options Outstanding, Beginning		884,849	195,000
Weighted Average Exercise Price Per Share, Beginning	[1]	$ 2.19	$ 1.56
Weighted Average Remaining Contractual Life		5 years 8 months 12 days	6 years 3 months 18 days	6 years 10 months 24 days
Aggregate Intrinsic Value, Beginning	[2]	$ 307,750	$ 100,200
Options Outstanding, Granted		822,605	714,849
Weighted Average Exercise Price Per Share, Granted	[1]	$ 1.77	$ 2.37
Options Outstanding, Cancelled		(198,332)	(25,000)
Weighted Average Exercise Price Per Share, Cancelled	[1]	$ 2.03	$ 2.46
Options Outstanding, Ending		1,509,122	884,849	195,000
Weighted Average Exercise Price Per Share, Ending	[1]	$ 1.98	$ 2.19	$ 1.56
Aggregate Intrinsic Value, Ending	[2]		$ 307,750	$ 100,200
Options exercisable		572,415
[1]The exercise price of each option granted during the period shown above was equal to the market price of the underlying stock on the date of grant.[2]The aggregate intrinsic value of stock options outstanding was based on our closing stock price on the last trading day of this period. The closing stock price at the end of the period (March 31, 2024) was $ 1.07

SCHEDULE OF STOCK OPTION ACTI_2

SCHEDULE OF STOCK OPTION ACTIVITY (Details) (Parenthetical) - $ / shares	Mar. 31, 2024	Feb. 29, 2024
Equity [Abstract]
Debt Instrument, Convertible, Conversion Price	$ 1.07	$ 0.75

SCHEDULE OF ADDITIONAL INFORMAT

SCHEDULE OF ADDITIONAL INFORMATION ABOUT STOCK OPTIONS (Details) - $ / shares	12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Equity [Abstract]
Non-vested options, beginning of year	709,394	195,000
Non -vested options, end of year	936,707	709,394
Vested options, end of year	572,415	175,455
Weighted-average grant date fair value, non-vested options, beginning of year	$ 2.23	$ 1.56
Weighted-average grant date fair value, non-vested options, end of year	1.84	2.23
Weighted-average grant date fair value, vested options, end of year	2.21	2.01
Weighted-average grant date fair value, forfeited options, during the year	$ 2.03

SCHEDULE OF WARRANT_S USING BLA

SCHEDULE OF WARRANT’S USING BLACK-SCHOLES VALUATION (Details) - $ / shares	12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Accumulated Other Comprehensive Income (Loss) [Line Items]
Term (years)	6 years	7 years
Volatility, minimum	75.90%	111.70%
Volatility, maximum	95.70%	146.90%
Risk-free rate, minimum	3.46%	2.96%
Risk-free rate, maximum	4.52%	4.35%
Minimum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stock price on valuation date	$ 1.20	$ 1.87
Maximum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stock price on valuation date	$ 2.75	$ 2.79
Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Volatility, minimum	75.90%
Volatility, maximum	95.70%
Risk-free rate, minimum	3.46%
Risk-free rate, maximum	4.52%
Warrant [Member] | Minimum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stock price on valuation date	$ 1.07
Exercise price	$ 1.20
Term (years)	2 years
Warrant [Member] | Maximum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stock price on valuation date	$ 2.15
Exercise price	$ 2.75
Term (years)	3 years

SCHEDULE OF WARRANT ACTIVITY (D

SCHEDULE OF WARRANT ACTIVITY (Details) - Warrant [Member] - $ / shares	12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of Warrants, Outstanding, Beginning balance	3,562,817	3,757,484
Weighted-Average Exercise Price, Outstanding, Beginning balance	$ 5.05	$ 4.95
Warrants Exercisable, Outstanding, Beginning balance	3,540,317	3,693,734
Weighted-Average Exercisable Price, Beginning balance	$ 5.07	$ 5
Number of Warrants, Exercised for cash		(48,664)
Weighted-Average Exercise Price, Exercised for cash		$ (1.36)
Number of Warrants, Granted and issued	4,386,463
Weighted-Average Exercise Price, Granted and issued	$ 1.80
Number of Warrants, Cashless warrant exercises	(63,584)
Weighted-Average Exercise Price, Cashless warrant exercises	$ (1.34)
Number of Warrants, Expired	(16,750)	(146,003)
Weighted-Average Exercise Price, Expired	$ (4.18)	$ (3.70)
Number of Warrants, Outstanding, Ending balance	7,768,946	3,562,817
Weighted-Average Exercise Price, Outstanding, Ending balance	$ 3.29	$ 5.05
Warrants Exercisable, Outstanding, Ending balance	7,768,946	3,540,317
Weighted-Average Exercisable Price, Ending balance	$ 3.28	$ 5.07

SCHEDULE OF RANGE OF WARRANT PR

SCHEDULE OF RANGE OF WARRANT PRICES (Details) - $ / shares	12 Months Ended
	Mar. 31, 2024	Feb. 02, 2024	Mar. 31, 2023	Mar. 31, 2022
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrant exercise price		$ 1.50
Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of Warrants, Outstanding	7,768,946
Weighted-Average Exercise Price, outstanding	$ 3.29		$ 5.05	$ 4.95
Weighted-Average Remaining Contractual Life (Years), Outstanding	2 years 6 months 14 days
Number of Warrants, Exercisable	4,075,537
Weighted-Average Exercise Price, Exercisable	$ 4.67
Warrant [Member] | Range One [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of Warrants, Outstanding	4,189,952
Weighted-Average Exercise Price, outstanding	$ 1.63
Weighted-Average Remaining Contractual Life (Years), Outstanding	2 years 9 months 18 days
Number of Warrants, Exercisable	635,713
Weighted-Average Exercise Price, Exercisable	$ 1.43
Warrant [Member] | Range One [Member] | Minimum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrant exercise price	1.20
Warrant [Member] | Range One [Member] | Maximum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrant exercise price	$ 2
Warrant [Member] | Range Two [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of Warrants, Outstanding	535,438
Weighted-Average Exercise Price, outstanding	$ 2.54
Weighted-Average Remaining Contractual Life (Years), Outstanding	1 year 5 months 23 days
Number of Warrants, Exercisable	396,268
Weighted-Average Exercise Price, Exercisable	$ 2.50
Warrant [Member] | Range Two [Member] | Minimum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrant exercise price	2.01
Warrant [Member] | Range Two [Member] | Maximum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrant exercise price	$ 4
Warrant [Member] | Range Three [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of Warrants, Outstanding	3,043,556
Weighted-Average Exercise Price, outstanding	$ 5.63
Weighted-Average Remaining Contractual Life (Years), Outstanding	2 years 7 months 9 days
Number of Warrants, Exercisable	3,043,556
Weighted-Average Exercise Price, Exercisable	$ 5.63
Warrant [Member] | Range Three [Member] | Minimum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrant exercise price	4.01
Warrant [Member] | Range Three [Member] | Maximum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrant exercise price	$ 5.63

STOCKHOLDERS_ EQUITY (Details N

STOCKHOLDERS’ EQUITY (Details Narrative) - USD ($)									1 Months Ended														2 Months Ended		3 Months Ended				12 Months Ended
	Apr. 15, 2024	Feb. 05, 2024	Feb. 02, 2024	Dec. 06, 2023	Aug. 11, 2023	Aug. 04, 2023	Jul. 27, 2023	Oct. 14, 2022	Dec. 31, 2024	Nov. 30, 2024	Feb. 29, 2024	Jan. 31, 2024	Dec. 31, 2023	Oct. 31, 2023	Aug. 31, 2023	Apr. 30, 2023	Mar. 31, 2023	Jan. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Aug. 31, 2022	Jul. 31, 2022	Sep. 30, 2023	Aug. 31, 2023	Mar. 31, 2024	Dec. 31, 2023	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2022	Aug. 10, 2023	Oct. 13, 2022	Jul. 10, 2020	Jan. 31, 2020
Accumulated Other Comprehensive Income (Loss) [Line Items]
Aggregate amount of convertiable promissory note																													$ 670,000
Interest rate														10%																					6%
Convertible conversion price											$ 0.75														$ 1.07				$ 1.07
Debentures conversion, shares issued											164,340
Warrant exercise price			$ 1.50
Loss on extinguishment of debt																													$ 534,366
Debetures conversion, value of shares issued											$ 123,255
Interest income																													(6,463)	$ 15,844
Value of warrants and additional shares issued																													$ 509,310
Accrued interest											$ 3,255
Number of shares sold			1,386,469								152,768	1,386,469	352,224	125,000	1,200,002	793,585		610,011												137,500
Sale price per share			$ 0.90												$ 1.50	$ 2.75		$ 2.32						$ 1.50
Warrants sale of stock, shares																									4,386,463				4,386,463
Proceeds from offering of shares												$ 1,247,819	$ 290,000	$ 200,000	$ 1,775,782	$ 2,182,359	$ 137,500
Payments of stock issuance costs															24,218	$ 88,765
Proceeds from issuance of private placement			$ 1,247,819									317,000
Proceeds from stock plans												$ 27,000
Proceeds from issuance of common stock				$ 145,820																										$ 137,500
Net proceeds				$ 171,180														$ 1,389,245
Share issued for services																		101,000											6,108,400
Vesting of restricted stock units in lieu of compensation																													$ 115,595
Stock issued for services, value																										$ 293,123			1,490,841	399,840
Stock repurchased during period shares														250,000
Stock repurchased during period value														$ 537,500
Registered Offering valued											$ 1,247,819
Proceeds from warrant exercise																														66,558
Warrant cash proceeds
Share issued value for services																		$ 349,920											6,527,439	1,389,245
Amortization of stock issued for services																													442,559	399,840
Stock-based compensation																													$ 2,109,783	$ 1,462,768
Stock options contractual term																													5 years 8 months 12 days	6 years 3 months 18 days	6 years 10 months 24 days
Minimum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Options exercisable, exercise price																									$ 1.39				$ 1.39
Maximum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Options exercisable, exercise price																									$ 2.79				$ 2.79
Forecast [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares sold									674,000	674,000
Proceeds from offering of shares									$ 959,033	$ 959,033
Deferred offering costs									65,779	65,779
Proceeds from issuance initial public offering									$ 893,254	$ 893,254
Convertible Debentures [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Convertible debentures amount															577,500
Accrued interest															$ 27,500
Debentures conversion, shares issued															385,000
Sale price per share															$ 1.50									1.50
Warrant Holders [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares sold																					24,447		34,678
Sale price per share															$ 1.34						$ 1.41			$ 1.34
Warrants sale of stock, shares															63,584									63,584
Warrant cash proceeds																					$ 34,370
Restricted Stock Units (RSUs) [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Vesting of restricted stock units, shares																	122,684	10,000	11,250	1,250	22,000	10,000		28,250	109,834	11,250				177,184
Time-Based Restricted Stock Units [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stock-based compensation																													$ 667,668	$ 606,014
Unrecognized pre-tax compensation expenses																									$ 56,000				$ 56,000
Unrecognized compensation expenses recognition period																													6 months
Share-Based Payment Arrangement, Option [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stock-based compensation																													$ 1,102,522	662,429
Unrecognized compensation expenses recognition period																													1 year 7 months 6 days
Stock options vesting period																													3 years
Stock options contractual term																													7 years
Unrecognized compensation expenses																									$ 1,087,401				$ 1,087,401
Registered Offering [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants sale of stock, shares															1,200,002									1,200,002
Registered Offering valued															$ 1,273,365
Private Offering [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants sale of stock, shares											1,639,237	430,000	352,224													352,224
Convertible Note [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Maturity date		May 14, 2024
Interest rate		10%
Convertible conversion price		$ 0.75
Debentures conversion, shares issued		164,340
Debt Instrument, Face Amount		$ 120,000
Accrued interest		$ 3,255
Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stock-based compensation																													339,644	$ 41,662
Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Value of warrants and additional shares issued
Share issued for services																													4,684,048	610,011
Vesting of restricted stock units in lieu of compensation, shares																													50,500
Vesting of restricted stock units in lieu of compensation																													$ 51
Stock issued for services, shares																													890,500	126,000
Stock issued for services, value																													$ 891	$ 126
Vesting of restricted stock units, shares																													149,334	177,184
Warrant cash proceeds																													$ 149	$ 177
Share issued value for services																													4,685	$ 610
Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Share issued for services																														961,859
Chief Executive Officer [Member] | Restricted Stock Units (RSUs) [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Vesting of restricted stock units in lieu of compensation, shares															20,200													30,300
Vesting of restricted stock units in lieu of compensation															$ 41,006													$ 74,589
Vesting of restricted stock units, shares	150,000
Warrant cash proceeds	$ 90,000
Service Provider [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stock issued for services, shares																					25,000				324,000	167,004	349,498	49,998
Stock issued for services, value																					$ 49,920				$ 423,216		$ 740,978	$ 123,078
Service Provider [Member] | Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stock issued for services, shares															300,000
Stock issued for services, value															$ 234,741
Warrant Holders [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrant exercise price																						$ 1.33
Share issued for services																						24,217
Proceeds from warrant exercise																						$ 32,188
Employees and Directors [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Fair value of options on the date of grant																													$ 1,107,799	$ 984,552
Service Provider One [Member] | Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stock issued for services, shares															80,000
Service Provider One [Member] | Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stock issued for services, value															$ 87,485
2020 Equity Incentive Plan [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares of common stock authorized																																		1,000,000
Amended Plan [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares of common stock authorized								3,000,000																									1,000,000
Number of shares available to grant																									822,605				822,605
Common stock available and reserved to be issued								3,000,000
Sale of common stock							$ 2,000,000
Amended Plan [Member] | Non-employee Director [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Maximum aggregate number of shares of common stock granted								10,000
Debenture Subscription Agreements [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Aggregate amount of convertiable promissory note							$ 550,000
Maturity date							Jan. 26, 2024
Interest rate							10%
Convertible Debenture Conversion Agreements [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Maturity date					Jan. 26, 2024
Convertible conversion price					$ 1.50																											$ 1.60
Convertible debentures amount					$ 550,000
Accrued interest					$ 27,500
Debentures conversion, shares issued					385,000
Debentures conversion, warrants issued					385,000
Warrant exercise price					$ 2
Loss on extinguishment of debt																													$ 534,366
Interest expense					$ 25,056
Interest income					2,444
Convertible Debenture Conversion Agreements [Member] | Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Debentures conversion, shares issued															385,000
Debetures conversion, value of shares issued					463,476										$ 463,476
Convertible Debenture Conversion Agreements [Member] | Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Debetures conversion, value of shares issued					$ 45,834
Purchase Agreement [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrant exercise price						$ 2
Number of shares sold						1,200,002
Sale price per share						$ 1.50																			$ 1.50				$ 1.50
Warrants sale of stock, shares						1,200,002
Proceeds from offering of shares						$ 1,775,782
Payments of stock issuance costs						24,218
Purchase Agreement [Member] | Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Proceeds from offering of shares						1,273,365
Purchase Agreement [Member] | Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Proceeds from offering of shares						$ 502,417
Purchase Agreements [Member] | Five Investor [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares sold				352,224
Sale price per share				$ 0.90

SCHEDULE OF DEFERRED TAX (Detai

SCHEDULE OF DEFERRED TAX (Details) - USD ($)	Mar. 31, 2024	Mar. 31, 2023
Income Tax Disclosure [Abstract]
Net operating loss carryforwards	$ 10,786,000	$ 8,311,000
Stock compensation	1,539,000	933,000
Other	74,000	118,000
Total deferred tax assets	12,399,000	9,362,000
Valuation allowance	(12,399,000)	(9,362,000)
Net deferred tax assets

SCHEDULE OF EFFECTIVE INCOME TA

SCHEDULE OF EFFECTIVE INCOME TAX RATE RECONCILIATION (Details)	12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Tax Disclosure [Abstract]
Tax benefits at statutory rate	21%	21%
State income tax benefit, net of federal	7.70%	7.70%
Gross Effective Rate	28.70%	28.70%
Valuation allowance	(28.70%)	(28.70%)
Net effective rate

INCOME TAXES (Details Narrative

INCOME TAXES (Details Narrative) - USD ($)	12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Net operating loss carry forwards	$ 37,500,000	$ 29,000,000
Deferred tax assets operating loss carryforwards	10,786,000	8,311,000
Change in the valuation allowance	3,037,000	1,613,000
Accrued interest and penalties related to uncertain tax positions	0	$ 0
Gel-Del Technologies, Inc [Member]
Net operating loss carry forwards	7,000,000
Accumulated pre-merger operating loss carryforwards	$ 7,000,000

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative) - USD ($)					1 Months Ended													2 Months Ended	3 Months Ended		12 Months Ended
	Apr. 29, 2024	Apr. 15, 2024	Apr. 01, 2024	Feb. 02, 2024	May 15, 2024	Feb. 29, 2024	Jan. 31, 2024	Dec. 31, 2023	Oct. 31, 2023	Aug. 31, 2023	Apr. 30, 2023	Mar. 31, 2023	Jan. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Aug. 31, 2022	Jul. 31, 2022	Aug. 31, 2023	Mar. 31, 2024	Dec. 31, 2023	Mar. 31, 2024	Mar. 31, 2023
Subsequent Event [Line Items]
Number of shares sold				1,386,469		152,768	1,386,469	352,224	125,000	1,200,002	793,585		610,011									137,500
Sale of stock price per share				$ 0.90						$ 1.50	$ 2.75		$ 2.32					$ 1.50
Warrant price per share				$ 1.50
Proceeds from issuance of PrivatePlacement				$ 1,247,819			$ 317,000
Number of restricted shares issued, value
Conversion converted instrument amount						$ 123,255
Accrued interest						$ 3,255
Number of converted shares issued						164,340
Convertible conversion price						$ 0.75													$ 1.07		$ 1.07
Common Stock [Member]
Subsequent Event [Line Items]
Number of restricted shares issued																					149,334	177,184
Number of restricted shares issued, value																					$ 149	$ 177
Restricted Stock Units (RSUs) [Member]
Subsequent Event [Line Items]
Number of restricted shares issued												122,684	10,000	11,250	1,250	22,000	10,000	28,250	109,834	11,250		177,184
Restricted Stock Units (RSUs) [Member] | Chief Executive Officer [Member]
Subsequent Event [Line Items]
Number of restricted shares issued		150,000
Number of restricted shares issued, value		$ 90,000
Subsequent Event [Member]
Subsequent Event [Line Items]
Number of shares sold			1,889,434
Warrants to purchase shares	430,798		1,889,434
Warrant price per share	$ 1.50		$ 1.50
Warrant term	3 years		3 years
Proceeds from issuance of PrivatePlacement			$ 1,322,600
Conversion converted instrument amount	$ 300,000
Accrued interest	$ 1,558
Number of converted shares issued	430,798
Convertible conversion price	$ 0.70
Subsequent Event [Member] | Common Stock [Member]
Subsequent Event [Line Items]
Number of converted shares issued	430,798
Subsequent Event [Member] | Restricted Stock Units (RSUs) [Member] | Three Investor [Member]
Subsequent Event [Line Items]
Number of restricted shares issued					376,000
Number of restricted shares issued, value					$ 201,912
Subsequent Event [Member] | Private Placement [Member]
Subsequent Event [Line Items]
Number of shares sold			1,889,434
Sale of stock price per share			$ 0.70